SCHEMBL16635824

SCHEMBL16635824

CN=S1(=O)CCN(c2ccc(Br)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 3/20 0.39
USP2 O75604 1/20 0.39
HRH3 Q9Y5N1 2/20 0.37
MAPT P10636 6/20 0.37
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
MEN1 O00255 1/20 0.35
APAF1 O14727 1/20 0.35
MAPK1 P28482 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GAA P10253 2/20 0.35
ADRA2C P18825 1/20 0.35
GFER P55789 1/20 0.35
PTK2B Q14289 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1235260 0.81 KDM4E (0.59) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL27389233 0.79 ALDH1A1 (0.42) KDM4EALDH1A1KMT2AHRH3MAPT
SCHEMBL16635950 0.78 AKR1C3 (0.44) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL30912432 0.77 SIRT6 (0.64) AKR1C3ALDH1A1KMT2AMAPTMEN1
SCHEMBL16635667 0.76 AKR1C3 (0.40) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL24185308 0.73 HPGD (0.60) ALDH1A1KMT2A
SCHEMBL31252540 0.73 AKR1C3 (0.57) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL27945382 0.73 AKR1C3 (0.57) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL28089645 0.73 AKR1C3 (0.46) AKR1C3KDM4EALDH1A1KMT2AUSP2
SCHEMBL19402 0.72 ALDH1A1 (0.63) AKR1C3KDM4EALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
EP-3104705-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-03 EP disclosed
US-9656990-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-05-23 US disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
EP-3104705-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-12-21 EP disclosed
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-08 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015123089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-08-20 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355502-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ AKR1C3 2461/4885KDM4E 2274/4885ALDH1A1 4582/4885
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ AKR1C3 2461/4885KDM4E 2274/4885ALDH1A1 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.